Mitapivat Sulfate Patent Expiration
Mitapivat Sulfate is used for treating hemolytic anemia in adults with pyruvate kinase (PK) deficiency. It was first introduced by Agios Pharmaceuticals Inc
Mitapivat Sulfate Patents
Given below is the list of patents protecting Mitapivat Sulfate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Pyrukynd | US11878049 | Mitapivat therapy and modulators of cytochrome P450 | Jul 31, 2041 | Agios Pharms Inc |
| Pyrukynd | US11254652 | Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide | Nov 21, 2038 | Agios Pharms Inc |
| Pyrukynd | US11234976 | Methods of using pyruvate kinase activators | Oct 11, 2038 | Agios Pharms Inc |
| Pyrukynd | US11793806 | Pyruvate kinase activators for use in therapy | Apr 12, 2033 | Agios Pharms Inc |
| Pyrukynd | US9193701 | Pyruvate kinase activators for use in therapy | Oct 26, 2032 | Agios Pharms Inc |
| Pyrukynd | US10632114 | Pyruvate kinase activators for use in therapy | May 03, 2032 | Agios Pharms Inc |
| Pyrukynd | US9682080 | Pyruvate kinase activators for use in therapy | May 03, 2032 | Agios Pharms Inc |
| Pyrukynd | US9980961 | Pyruvate kinase activators for use in therapy | May 03, 2032 | Agios Pharms Inc |
| Pyrukynd | US8785450 | Therapeutic compounds and compositions | Feb 24, 2031 | Agios Pharms Inc |
| Pyrukynd | USRE49582 | Therapeutic compounds and compositions | Feb 24, 2031 | Agios Pharms Inc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Mitapivat Sulfate's patents.
Latest Legal Activities on Mitapivat Sulfate's Patents
Given below is the list recent legal activities going on the following patents of Mitapivat Sulfate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 14 Mar, 2024 | US9193701 |
| transaction for FDA Determination of Regulatory Review Period | 28 Feb, 2024 | US9193701 |
| Mail Patent eCofC Notification | 27 Feb, 2024 | US11878049 |
| Recordation of Patent eCertificate of Correction | 27 Feb, 2024 | US11878049 |
| Patent eCofC Notification | 27 Feb, 2024 | US11878049 |
| Email Notification Critical | 27 Feb, 2024 | US11878049 |
| Post Issue Communication - Certificate of Correction | 05 Feb, 2024 | US11878049 |
| Mail Patent eGrant Notification | 23 Jan, 2024 | US11878049 |
| Email Notification Critical | 23 Jan, 2024 | US11878049 |
| Patent eGrant Notification | 23 Jan, 2024 | US11878049 |
Mitapivat Sulfate's Family Patents
